Search results
Bird Flu: What's The Latest And How Worried Should We Be?
IFLScience· 5 hours agoBird flu seems to be perennially in the news at the moment, and with more and more species...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 9 hours agoThe Covid vaccine maker came out of the March quarter with a $3.07 loss per share, reversing from a...
No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Key
IFLScience· 5 hours agoA new vaccine strategy could spell the end of yearly flu shots, by targeting part of the virus that...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 3 hours agoBut Moderna expects the lion's share of its sales to come in the second half of 2024. That lines up...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 9 hours agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
The Dow jumps 350 points and the S&P 500 looks to break a losing streak as investors wait for Apple
Quartz· 37 minutes agoInvestors have also kept an eye on the April jobs report due on Friday
Are your kids scared of needles? Health First helps remove pain, fear of getting a shot
Florida Today via Yahoo News· 5 hours agoMcGregor said. “I don’t like needles even now.” Children who develop intense anxiety around “jabs”...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 8 hours agoModerna stock soared on Wednesday after its first-quarter earnings report sailed past Wall Street’s...
GSK raises forecasts on strong vaccine, HIV drug sales
BioPharma Dive via Yahoo Finance· 1 day agoSales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Digital Journal· 9 hours agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 ...